Journal of Clinical Hepatology
This article investigates the impact of centromere antibody (ACA) on the clinical characteristics and prognosis of patients with primary biliary cholangitis (PBC). By retrospectively analyzing the clinical data of 749 PBC patients, the study compares the differences between the positive (n=147) and negative (n=602) ACA groups in terms of clinical classification, ursodeoxycholic acid (UDCA) response, and GLOBE/UK-PBC prognosis scores. The results show that the positive ACA group is older and has a higher proportion of females, with a significantly higher proportion of portal hypertension type (48.3% vs 27.6%), while the proportion of jaundice/liver failure type is lower (24.5% vs 38.5%). One-year follow-up data show that the positive ACA group has a higher GLOBE score (>0.3 accounted for 92.5%), indicating a potential poor prognosis trend, but after propensity score matching, there were no significant differences between the two groups in UDCA response rate, GLOBE, and UK-PBC scores. The innovation lies in the systematic analysis of the impact of ACA on PBC clinical classification, combined with modern prognosis models (GLOBE and UK-PBC scores) for comprehensive evaluation, while using propensity score matching to reduce confounding bias, improving the reliability of the results. The study provides new evidence to support the clinical significance of ACA in PBC.
This study explores the impact of centromere antibody (ACA) on the clinical characteristics and prognosis of patients with primary biliary cholangitis (PBC), which has important clinical significance. By comparing the clinical classification, UDCA treatment response, and prognosis scores (GLOBE, UK-PBC) between patients with positive and negative ACA, it reveals the association between ACA status and disease phenotype. The study finds that patients with positive ACA more commonly present with portal hypertension type PBC, with a lower proportion of jaundice/liver failure type, suggesting that it may affect the disease progression pathway. In addition, positive ACA is associated with more severe biliary reactions, which may promote the development of portal hypertension by promoting biliary injury and fibrosis, providing an immunological explanation for the heterogeneity of PBC. Although there is controversy about the impact of ACA on prognosis, it serves as a potential biomarker to help identify high-risk patients early and optimize individual management strategies. The study is based on a large sample retrospective analysis, including 749 patients, enhancing the reliability of the conclusions. The research results can provide a basis for clinical evaluation of the condition and prediction of outcomes, while expanding the understanding of the immunological mechanisms of autoimmune liver diseases. Ethical approval and funding support also ensure the standardization and scientific nature of the research.
Objective: To investigate the impact of anticentromere antibody (ACA) on the clinical features and prognosis of patients with primary b…
